J&J Pipeline On Track; Tapentadol Filing Expected This Week
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.
You may also be interested in...
Centocor: Ustekinumab Works in Psoriasis After One Year
Second Phase III pivotal study backs fewer-dose benefit
Centocor: Ustekinumab Works in Psoriasis After One Year
Second Phase III pivotal study backs fewer-dose benefit
Johnson & Johnson Files NDA For Oral Analgesic Tapentadol
Filing gives tapentadol a Nov. 22 user fee date with standard review.